About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT04111211

Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits

Dementia is a clinical syndrome that is the result of distinct underlying pathologies including Alzheimer's disease (AD). Despite more than two decades of research on prevention and treatment of demen...

Lead sponsor: University Hospital, Bordeaux•26 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Bordeaux

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants aged over 18 year-old
•Being included in Memento cohort
•Affiliated person or beneficiary of a social security scheme.
•Participants capable of expressing non objection
•Non objection expressed by the tutor for participants under tutorship
•Non objection expressed by the participant assisted by their guardian for participants under guardianship
•Non objection expressed by the trusted person (in accordance with art. L1111-6 of Code de la Santé Publique) for participants without the capacity to express non-objection and who are not under legal protection measure

Exclusion Criteria

•Expressing opposition to participate in Memento-Plus

Related studies

RECRUITINGPhase 3

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

NCT07571161 · Alzheimer Disease

RECRUITINGPhase 2

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321 · Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis

RECRUITINGPhase 3

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229 · Alzheimer Disease, Agitation

RECRUITINGPhase 4

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470 · Alzheimer Disease

Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

NCT04579120 · Alzheimer Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 17, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1,028

Start dateDec 2019

Last updatedFeb 17, 2025

Condition

Alzheimer Disease

Locations shown

CHU d'Amiens

Amiens

AP-HP - CHU Avicenne

Bobigny

CHU de Bordeaux - Pellegrin

Bordeaux

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2025Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions